Here are the 10-Q quarterly reports from SeaStar Medical Holding Corporation Warrant (ICUCW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ICUCW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICUCW filings page.
SeaStar Medical Holding Corporation reported continued early commercial progress but significant losses for the three and six months ended June 30, 2026. Net revenue was $615,000 in the quarter and $1.11 million year-to-date, up from $338,000 and $631,000 a year earlier, driven by increased adoption of its FDA-approved pediatric QUELIMMUNE therapy for acute kidney injury.
The company remains deeply loss-making. It recorded a net loss of $3.7 million for the quarter and $7.3 million for the first half of 2026, with operating expenses of $4.4 million in the quarter largely from research and development on its adult SCD program and general and administrative costs. Cash declined to $7.0 million at June 30, 2026, down from $12.0 million at year-end, and operating activities used $5.8 million of cash in the first half.
Management states that existing cash will not fund operations, including clinical trials, for 12 months and that this raises substantial doubt about the company’s ability to continue as a going concern. SeaStar is relying on equity financing facilities, including an at-the-market program and a standby equity purchase agreement, and has raised modest additional capital, while advancing pivotal adult AKI and other clinical studies on its SCD platform.
SeaStar Medical Holding Corporation reported a quarterly net loss of $3.5 million on $0.5 million of revenue for the three months ended March 31, 2026. Revenue rose from $0.3 million a year earlier as QUELIMMUNE pediatric therapy adoption increased, but spending on research and development ($2.3 million) and general and administrative costs ($1.7 million) kept the company unprofitable.
Cash totaled $9.3 million with total assets of $11.3 million and an accumulated deficit of $155.2 million. Management states that existing cash will not fund operations for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. SeaStar highlights ongoing commercialization of QUELIMMUNE, pivotal NEUTRALIZE-AKI and other adult trials, and notes a dismissed securities class action and a pending derivative suit.